28.02.2007 16:40:00
|
Medtronic Announces Succession Plans for CEO and COO
Medtronic, Inc. (NYSE:MDT) announced today the implementation of a
succession plan that was developed by the board of directors over the
past several years for its chief executive officer and chief operating
officer positions. Effective August 23, 2007, at the company’s
next annual shareholders meeting, William A. Hawkins, III, currently the
company’s president and COO, will become
president and CEO. At the same time, Michael F. DeMane, currently senior
vice president and president of Medtronic’s
business in Europe, Canada, Latin America and Emerging Markets, will
become Medtronic’s COO. After Hawkins and
DeMane assume their new responsibilities, Arthur D. Collins, Jr.,
Medtronic chairman and CEO, will remain as a director and chairman of
the board until the annual shareholders meeting in August 2008. Also,
the board plans to elect Hawkins to the Medtronic Board of Directors in
March at the next regularly scheduled board meeting.
In his remarks to employees at the company’s
quarterly Chairman’s Briefing earlier today,
Collins said that Medtronic has a long history of carefully planning for
and implementing smooth CEO transitions, and the process leading up to
today’s announcement was no exception.
"Medtronic is well positioned to continue our
strong record of success and we are fortunate to have two individuals of
Bill’s and Michael’s
caliber to step into the CEO and COO positions and work as a team. Both
individuals have broad experience and well established track records,
and the board is unanimous in its belief that their leadership will
continue to successfully move Medtronic forward in the future,”
Collins said.
Jean-Pierre Rosso, Medtronic Board member and chairman of the Corporate
Governance Committee said, "After Art
informed the board of his retirement timetable several years ago, we
carefully considered succession alternatives when developing the plan
that was announced today.” Rosso added, "Art’s
highly professional, steady leadership has been clearly evident as the
company expanded and consistently posted strong growth for the more than
13 years he has served as COO and CEO. He has played a major role in
representing Medtronic and the industry around the world, and his
contributions are well recognized inside and outside the company. The
board is also confident that Bill and Michael will work together to
further strengthen the company’s leadership
position in the future.” "This is an incredibly exciting and dynamic
time for Medtronic and the medical technology industry,”
said Hawkins. "I am honored to have the
opportunity to continue Medtronic’s strong
leadership and commitment to serving our patients and customers,
shareholders and employees.”
Collins, 59, assumed the role of chief executive officer of Medtronic in
April 2001 and became chairman of the board in April 2002. He was
elected chief operating officer and member of the board of directors in
1994 and president in 1996. He joined the company in 1992 as corporate
executive vice president and president of Medtronic International with
responsibility for all Medtronic operations outside the United States.
Collins joined Medtronic from Abbott Laboratories where he had been
corporate vice president with responsibility for Abbott’s
worldwide diagnostic business units since 1986. He began his 14-year
career with Abbott in 1978 and held a number of general management
positions in the United States and Europe. Before joining Abbott, he was
a consultant with Booz, Allen & Hamilton and served as an officer in the
United States Navy. Collins received a bachelor’s
of science degree and a Doctor of Laws honorary degree from Miami
University in Oxford, Ohio. He also holds a master’s
of Business Administration degree from the Wharton School of the
University of Pennsylvania where he was a member of the undergraduate
faculty. He currently serves on the board of directors at U.S. Bancorp
and Cargill, and is a member of the board of overseers of the Wharton
School at the University of Pennsylvania and the board of The Institute
of Health Technology Studies.
Hawkins, 53, was elected president and chief operating officer of
Medtronic in May 2004. Previously, he was president of Medtronic’s
Vascular business. Hawkins joined Medtronic in January 2002 from
Novoste, where he had been president and chief executive officer since
1998. He started his medical technology career in 1977, and subsequently
held numerous positions including corporate vice president and president
of the Sherwood Davis and Geck division of American Home Products;
president of the Ethicon Endo-Surgery organization of Johnson & Johnson;
president, Devices for Vascular Intervention and U.S. Operations, for
Guidant; and several executive positions including president of the IVAC
division of Eli Lilly. Hawkins received his bachelor’s
of science degree in electrical and biomedical engineering from Duke
University where he also conducted medical research in pathology. He
received a master’s of Business
Administration degree from the Darden School of Business, University of
Virginia. He is a member of the board of Visitors of the Engineering
School of Duke University, the board of Deluxe Corp., and a trustee of
the University of Virginia Darden School Foundation.
DeMane, 50, was appointed president of Medtronic Europe, Canada, Latin
America and Emerging Markets in August 2005. From 2002 to 2005, he
served as president of Medtronic Spinal, ENT (Ear, Nose and Throat), and
Navigation. Prior to that, he was president of Spinal Systems for
Medtronic Sofamor Danek, Medtronic’s Spinal
business. Before joining Medtronic, DeMane served from 1996 to 1998 as
managing director, Australia and New Zealand, for Smith & Nephew. He
came to that position following a series of research and development and
general management positions within Smith & Nephew. DeMane received his
bachelor’s of science degree in chemistry
from St. Lawrence University, continued his studies in engineering at
the University of Texas, and received his master’s
of science degree in bioengineering from Clemson University. He later
completed an advanced management program at the INSEAD School of
Management in Fontainebleau, France.
About Medtronic
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical technology –
alleviating pain, restoring health, and extending life for millions of
people around the world.
Any forward-looking statements are subject to risks and uncertainties
such as those described in Medtronic’s Annual
Report on Form 10-K for the year ended April 28, 2006. Actual
results may differ materially from anticipated results.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Medtronic Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Medtronic Inc.mehr Analysen
Indizes in diesem Artikel
S&P 500 | 6 051,09 | 0,00% | |
S&P 100 | 2 958,64 | 0,16% | |
NYSE US 100 | 16 915,96 | -0,37% |